Literature DB >> 16630062

Evidence for a role of CaMKIV in the development of opioid analgesic tolerance.

Shanelle W Ko1, Yongheng Jia, Hui Xu, Se-Jeong Yim, Dong-Hyuk Jang, Yong-Seok Lee, Ming-Gao Zhao, Hiroki Toyoda, Long-Jun Wu, Talal Chatila, Bong-Kiun Kaang, Min Zhuo.   

Abstract

cAMP response-element binding protein (CREB), a transcription factor involved in learning, memory and drug addiction, is phosphorylated by calcium-calmodulin-dependent protein kinase IV (CaMKIV). Here, we show that CaMKIV-knockout (KO) mice developed less analgesic tolerance after chronic morphine administration with no alteration in physical dependence or acute morphine-induced analgesia. The increase in phosphorylated CREB expression observed in wild-type mice after chronic morphine was absent in CaMKIV-KO mice, while there was no difference in the expression or phosphorylation of the micro-opioid receptor between groups. Morphine-treated CaMKIV-KO mice showed less G-protein uncoupling from the micro-opioid receptor than did wild-type mice, while uncoupling was similar in control wild-type and KO mice. In addition, morphine reduced inhibitory transmission to a greater degree in CaMKIV-KO mice than in controls after chronic morphine exposure. Our results provide novel evidence for the role of CaMKIV in the development of opioid analgesic tolerance but not physical dependence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630062     DOI: 10.1111/j.1460-9568.2006.04748.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  12 in total

1.  Potential genetic risk factors for chronic TMD: genetic associations from the OPPERA case control study.

Authors:  Shad B Smith; Dylan W Maixner; Joel D Greenspan; Ronald Dubner; Roger B Fillingim; Richard Ohrbach; Charles Knott; Gary D Slade; Eric Bair; Dustin G Gibson; Dmitri V Zaykin; Bruce S Weir; William Maixner; Luda Diatchenko
Journal:  J Pain       Date:  2011-11       Impact factor: 5.820

Review 2.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

Review 3.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

Review 4.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 5.  Control of alternative pre-mRNA splicing by Ca(++) signals.

Authors:  Jiuyong Xie
Journal:  Biochim Biophys Acta       Date:  2008-01-17

6.  Contribution of adrenomedullin to the switch of G protein-coupled μ-opioid receptors from Gi to Gs in the spinal dorsal horn following chronic morphine exposure in rats.

Authors:  Dongmei Wang; Juan Zeng; Qi Li; Jianzhong Huang; Réjean Couture; Yanguo Hong
Journal:  Br J Pharmacol       Date:  2016-02-25       Impact factor: 8.739

7.  Calcium/calmodulin-dependent protein kinase IV mediates acute nicotine-induced antinociception in acute thermal pain tests.

Authors:  Kia J Jackson; Mohamad I Damaj
Journal:  Behav Pharmacol       Date:  2013-12       Impact factor: 2.293

8.  Effect of KEPI (Ppp1r14c) deletion on morphine analgesia and tolerance in mice of different genetic backgrounds: when a knockout is near a relevant quantitative trait locus.

Authors:  J Drgonova; D B Zimonjic; F S Hall; G R Uhl
Journal:  Neuroscience       Date:  2009-10-09       Impact factor: 3.590

9.  CaMKIV Signaling Is Not Essential for the Maintenance of Intrinsic or Synaptic Properties in Mouse Visual Cortex.

Authors:  Nicholas F Trojanowski; Gina G Turrigiano
Journal:  eNeuro       Date:  2021-07-06

10.  Nicotine reward and affective nicotine withdrawal signs are attenuated in calcium/calmodulin-dependent protein kinase IV knockout mice.

Authors:  Kia J Jackson; Sarah S Sanjakdar; Xiangning Chen; M Imad Damaj
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.